Thank you for standing by. My name is Amy, and I will be your operator for today. At this time, I would like to welcome everyone to the AtaiBeckley EMP-01 Phase IIa Topline Data Conference Call.
However, an exploratory analysis of a pre-specified subgroup of patients with TP53 wild-type endometrial cancer showed a promising efficacy signal. In the SIENDO study, 263 patients were randomly ...
Here we report the exploratory analyses of clinical outcomes collected in the MAD and LTE periods of the BIIB080 phase 1b study. Recognizing that the study was not powered for the statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results